Weekly docetaxel in minimally pretreated cancer patients: A dose- escalation study focused on feasibility and cumulative toxicity of long-term administration

Annals of Oncology

Volumn 10, Issue 6, 1999, Pages 701-706

  Briasoulis, E ^a,d   Karavasilis, V ^a   Anastasopoulos, D ^b   Tzamakou, E ^a   Fountzilas, G ^c   Rammou, D ^a   Kostadima, V ^b   Pavlidis, N ^a  

^a Medical Oncology Department   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c AHEPA UNIVERSITY HOSPITAL   (Greece)

^d UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cancer; Cumulative toxicity; Docetaxel; Phase I; Weekly schedule

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; VINCRISTINE;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW TOXICITY; CANCER; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INFUSION; ELECTROPHYSIOLOGY; EYE DISEASE; FATIGUE; FEMALE; FLUID RETENTION; HUMAN; LONG TERM CARE; MALE; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; TAXOIDS;

EID: 0032815130     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008399712913     Document Type: Article

References (18)

1. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): A review of preclinical and clinical experience. Part 1: Preclinical experience. Anticancer Drugs 1995; 6: 339 55, 363-8.
2. Kavanagh JJ, Kudelka AP, de LC et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 1996; 2: 837-42.
3. Fumoleau P, Chevallier B, Kerbrat P et al. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Ann Oncol 1996; 7; 165-71.
4. Briasoulis E, Tzamakou E, Nicolaides C et al. Long-term weekly administration of paclitaxel in chemotherapy-naïve patients, phase I study: Single versus cumulative dose limiting toxicity. Proc Am Soc Clin Oncol 1997; 16: A811.
5. Klaassen U, Wilke H, Strumberg D et al. Phase I study with a weekly one-hour infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 1996; 32A: 547-9.
6. Seidman AD, Hudis CA, Albanel J et al. Dose-dense therapy with weekly one-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16: 3353 61.
7. Hennequin C, Giocanti N, Favaudon V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 1995; 71: 1194-8.
8. Extra J-M, Rousseau F, Bruno R et al. Phase I and pharmacokinetic study of Taxotere® (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993; 53: 1037-42.
9. Hande KR. The importance of drug scheduling in cancer chemotherapy: Etoposide as an example. Oncologist 1996; 1: 234-9.
10. Tomiak E, Piccart MJ, Kerger J et al. Phase I study of docetaxel administered as a one-hour intravenous infusion on a weekly basis. J Clin Oncol 1994; 12: 1458-67.
11. Hainsworth JD, Burris HA, Erland JB et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998; 16: 2164-8.
12. Kunitoh H, Watanabe K, Onoshi T et al. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: A Japanese cooperative study. J Clin Oncol 1996; 14: 1649-55.
13. Bruno R, Hille D, Riva A et al. Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16: 187 96.
14. Brink HM, Beex LV. Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Report of five cases and review of the literature. Doc Ophthalmol 1995; 90: 1-6.
15. Curran CF, Luce JK. Ocular adverse reactions associated with adriamycin (doxorubicin). Am J Ophthalmol 1989; 108: 709-11.
16. Piccart MJ, Klijn J, Paridaens R et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997; 15: 3149-55.
17. Trudeau ME, Eisenhauer EA, Higgins BP et al. Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada - Clinical Trials Group. J Clin Oncol 1996; 14: 422-8.
18. Hudis CA, Seidman AD, Crown JPA et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 58-65.